Korean Journal of Head & Neck Oncology (대한두경부종양학회지)

The Korean Society for Head and Neck Oncology (대한두경부종양학회)
권호 표지

Induction Chemotherapy with S-1 and Cisplatin in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck : A Single Center Experience

국소진행성 두경부편평상피암 환자를 대상으로 한 S1과 시스플라틴 병용 유도항암화학요법에 관한 연구

  • Yoon, Dok-Hyun (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Cho, Yoo-Jin (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Ji-Youn (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Sang-Yoon (Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Nam, Soon-Yuhl (Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Choi, Seung-Ho (Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Roh, Jong-Lyel (Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Lee, Sang-Wook (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Lee, Jeong-Hyun (Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Jae-Seung (Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Cho, Kyung-Ja (Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Sung-Bae (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine)
  • 윤덕현 (울산대학교 의과대학 서울아산병원 종양내과) ;
  • 조유진 (울산대학교 의과대학 서울아산병원 종양내과) ;
  • 김지연 (울산대학교 의과대학 서울아산병원 종양내과) ;
  • 김상윤 (울산대학교 의과대학 서울아산병원 이비인후과) ;
  • 남순열 (울산대학교 의과대학 서울아산병원 이비인후과) ;
  • 최승호 (울산대학교 의과대학 서울아산병원 이비인후과) ;
  • 노종렬 (울산대학교 의과대학 서울아산병원 이비인후과) ;
  • 이상욱 (울산대학교 의과대학 서울아산병원 방사선종양학과) ;
  • 이정현 (울산대학교 의과대학 서울아산병원 영상의학과) ;
  • 김재승 (울산대학교 의과대학 서울아산병원 핵의학과) ;
  • 조경자 (울산대학교 의과대학 서울아산병원 병리과) ;
  • 김성배 (울산대학교 의과대학 서울아산병원 종양내과)
  • Received : 2011.05.30
  • Accepted : 2011.09.19
  • Published : 2011.11.25
Download PDF
⟨ Previous Next ⟩

Abstract

서 론: 5-FU와 cisplatin 병용항암화학요법은 국소진행성 두경부편평상피암의 유도화학요법으로 널리 사용되고 있는 요법이다. 저자들은 5-FU 대신 경구제재인 S-1을 cisplatin과 병용하는 복합항암요법의 효과와 안전성에 대해 연구하였다. 대상 및 방법: 저자들은 2007년 2월부터 2008년 12월까지 S1과 cisplatin의 복합유도화학요법을 시행받은 3/4기 구인두, 하인두, 후두, 구강 편평상피세포암 환자 52명의 치료결과를 후향적으로 분석하였다. 유도항암화학요법은 제 1일에 cisplatin(75 또는 60mg/$m^2$), 제1일부터 14일까지 S-1(40mg/$m^2$)을 1일 2회, 21일 간격으로 투여하였고 가능한 경우에는 항암방사선동시요법 또는 수술을 뒤이어 시행하였다. 결 과: 전체 52명 중 37명(71.2%)에서 부분반응을 보였으나 완전반응은 관찰되지 않았다. 2년 무진행생존율은 56.9%, 2년 전체생존율은 68.2%였다. 유도항암요법과 관련된 유해반응으로는 호중구감소증(71.2%) 및 빈혈(63.5%) 등과 같은 혈액학적 부작용이 가장 흔했다. 결 론: S-1과 cisplatin의 복합항암화학요법은 국소진행성 두경부편평상피암 환자를 대상으로 한 유도화학요법으로 적용이 가능한 것으로 판단된다.

Keywords

References

  1. Garavello W, Ciardo A, Spreafico R, Gaini RM. Risk factors for distant metastases in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2006;132:762-766. https://doi.org/10.1001/archotol.132.7.762
  2. Dimery IW, Hong WK. Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst. 1993;85:95- 111. https://doi.org/10.1093/jnci/85.2.95
  3. Paccagnella A, Orlando A, Marchiori C, Zorat PL, Cavaniglia G, Sileni VC, et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst. 1994; 86:265-272. https://doi.org/10.1093/jnci/86.4.265
  4. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamouscell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000;355:949- 955. https://doi.org/10.1016/S0140-6736(00)90011-4
  5. Pignon JP, le Maitre A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer(MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92:4-14. https://doi.org/10.1016/j.radonc.2009.04.014
  6. Fujii M, Tomita K, Nishijima W, Tsukuda M, Hasegawa Y, Ishitoya J, et al. Phase I/II study of s-1 plus cisplatin combination chemotherapy in patients with advanced/recurrent head and neck cancer. Jpn J Clin Oncol. 2010;40:214-221. https://doi.org/10.1093/jjco/hyp153
  7. Domenge C, Hill C, Lefebvre JL, De Raucourt D, Rhein B, Wibault P, et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tete et du Cou (GETTEC). Br J Cancer. 2000;83: 1594-1598. https://doi.org/10.1054/bjoc.2000.1512
  8. Rooney M, Kish J, Jacobs J, Kinzie J, Weaver A, Crissman J, et al. Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer. 1985;55:1123-1128. https://doi.org/10.1002/1097-0142(19850301)55:5<1123::AID-CNCR2820550530>3.0.CO;2-8
  9. Fukui Y, Oka T, Nagayama S, Danenberg PV, Danenberg KD, Fukushima M. Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis. Int J Mol Med. 2008;22:709-716.
  10. Inuyama Y, Kida A, Tsukuda M, Kohno N, Satake B. [Late phase II study of S-1 in patients with advanced head and neck cancer]. Gan To Kagaku Ryoho. 2001;28:1381-1390.
  11. Choi YJ, Chung JS, Shin HJ, Cho GJ, Wang SG, Lee BJ, et al. Induction chemotherapy with S-1 plus cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck. J Laryngol Otol. 2008;122:848-853.
  12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216. https://doi.org/10.1093/jnci/92.3.205
  13. D'Ambrosio DJ, Li T, Horwitz EM, Chen DY, Pollack A, Buyyounouski MK. Does treatment duration affect outcome after radiotherapy for prostate cancer? Int J Radiat Oncol Biol Phys. 2008;72:1402-1407. https://doi.org/10.1016/j.ijrobp.2008.03.011
  14. Chan AT, Teo PM, Johnson PJ. Nasopharyngeal cancer. Cancer Treat Res. 2003;114:275-293.
  15. Lee JL, Kang HJ, Kang YK, Ryu MH, Chang HM, Kim TW, et al. Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer. Cancer Chemother Pharmacol. 2008;61:837-845. https://doi.org/10.1007/s00280-007-0541-5
  16. Yoon DH, Kim SB. S-1 plus cisplatin: another option in the treatment of advanced head and neck cancer? Expert Rev Anticancer Ther. 2010;10:659-662. https://doi.org/10.1586/era.10.45
  17. Hitt R, Lopez-Pousa A, Martinez-Trufero J, Escrig V, Carles J, Rizo A, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2005;23:8636-8645. https://doi.org/10.1200/JCO.2004.00.1990
  18. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007; 357:1705-1715. https://doi.org/10.1056/NEJMoa070956
  19. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357:1695- 1704. https://doi.org/10.1056/NEJMoa071028
  20. Hitt R, Grau JJ, Lopez-Pousa A, Berrocal A, Garcia Giron C, Irigoyen A, et al. Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU follow by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC). J Clin Oncol. 2009; 27:15s(suppl; abstr 6009). https://doi.org/10.1200/JCO.2008.21.7695